Shareholders in AnaptysBio (NASDAQ:ANAB) Have Lost 60%, as Stock Drops 13% This Past Week

Simply Wall StDec 23 07:20 ET

Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $20

Moomoo NewsDec 20 13:31 ET · Ratings

J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $36

Moomoo NewsDec 20 13:31 ET · Ratings

AnaptysBio Price Target Cut to $36.00/Share From $66.00 by JP Morgan

Dow JonesDec 19 12:15 ET · Ratings

AnaptysBio Is Maintained at Overweight by JP Morgan

Dow JonesDec 19 12:15 ET · Ratings

Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Announces Target Price $20

Moomoo NewsDec 19 05:33 ET · Ratings